22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › CELLDEX THERAPEUTICS INC. › 2024-2025

CELLDEX THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and CELLDEX THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 12Ballot items
  • 191Asset managers, any item
  • 2,712Fund votes
  • June 5, 2025Meeting date

Results at a glance

Meeting of June 5, 2025: 12 items on CELLDEX THERAPEUTICS INC.’s Form 8-K, filed June 6, 2025: 9 elected · 3 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore CELLDEX THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by CELLDEX THERAPEUTICS INC.

These tallies are CELLDEX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 6, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

CELLDEX THERAPEUTICS INC. — official shareholder meeting results, meeting held June 5, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Anthony S. Marucci (Chief Executive Officer) 54,056,36060,785164,073 --4,031,935 99.9%Elected—
Elect Director: Keith L. Brownlie 53,883,737250,401147,080 --4,031,935 99.5%Elected—
Elect Director: Cheryl L. Cohen 53,969,213165,776146,229 --4,031,935 99.7%Elected—
Elect Director: Herbert J. Conrad 53,051,3161,082,802147,100 --4,031,935 98%Elected—
Elect Director: Rita I. Jain, M.D. 53,914,572207,007159,639 --4,031,935 99.6%Elected—
Elect Director: James J. Marino 53,832,714301,247147,257 --4,031,935 99.4%Elected—
Elect Director: Garry A. Neil, M.D. 53,900,408233,807147,003 --4,031,935 99.6%Elected—
Elect Director: Harry H. Penner, Jr. 53,773,546360,343147,329 --4,031,935 99.3%Elected—
Elect Director: Denice Torres 54,104,93729,828146,453 --4,031,935 99.9%Elected—
2. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 58,043,825119,347149,981 ---- 99.8%Approved—
3. An amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares 53,158,156963,067159,995 --4,031,935 98%Approved—
The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement. 53,482,418626,666172,134 --4,031,935 99%Approved—

Source: CELLDEX THERAPEUTICS INC., Form 8-K, filed with the SEC on June 6, 2025 — read the filing on EDGAR.

How asset managers voted at the CELLDEX THERAPEUTICS INC. 2024-2025 meeting

191 asset managers disclosed a vote on at least one CELLDEX THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Anthony S. Marucci (Chief Executive Officer)

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 54,056,360AGAINST: 60,785

Prior year: 98.7% for (June 13, 2024 meeting) ▲ 1.2 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Anthony S. Marucci

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Anthony S. Marucci (Chief Executive Officer)”): 54,056,360 for, 60,785 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,432,781 for, 9,367 abstained.

FOR
FOR: 27,432,781ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Anthony S. Marucci” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Cheryl L. Cohen

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 53,969,213AGAINST: 165,776

Prior year: 98.9% for (June 13, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Cheryl L. Cohen

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Cheryl L. Cohen”): 53,969,213 for, 165,776 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,431,614 for, 1,167 against, 9,367 abstained.

FOR
FOR: 27,431,614AGAINST: 1,167ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Cheryl L. Cohen” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Denice Torres

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.9% Majority: yes · of votes cast

FOR 99.9%
FOR: 54,104,937AGAINST: 29,828
Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Denice Torres

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Denice Torres”): 54,104,937 for, 29,828 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,432,781 for, 9,367 abstained.

FOR
FOR: 27,432,781ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Denice Torres” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Garry A. Neil, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 53,900,408AGAINST: 233,807

Prior year: 98.8% for (June 13, 2024 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Garry Neil, M.D.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Garry A. Neil, M.D.”): 53,900,408 for, 233,807 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,432,781 for, 9,367 abstained.

FOR
FOR: 27,432,781ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Garry Neil, M.D.” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Harry H. Penner, Jr.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 53,773,546AGAINST: 360,343

Prior year: 98.6% for (June 13, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Harry H. Penner, Jr.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Harry H. Penner, Jr.”): 53,773,546 for, 360,343 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,412,183 for, 20,598 against, 9,367 abstained.

FOR
FOR: 27,412,183AGAINST: 20,598ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Harry H. Penner, Jr.” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,77040 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust15,62419,391 00Mixed
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Herbert J. Conrad

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 53,051,316AGAINST: 1,082,802

Prior year: 97.3% for (June 13, 2024 meeting) ▲ 0.7 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Herbert J. Conrad

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Herbert J. Conrad”): 53,051,316 for, 1,082,802 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,213,534 for, 219,247 against, 9,367 abstained.

FOR
FOR: 27,213,534AGAINST: 219,247ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Herbert J. Conrad” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,682,0384,436 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,772,221158,656 00Mixed
State Street1,012,77040 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust15,62419,391 00Mixed
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: James J. Marino

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.4% Majority: yes · of votes cast

FOR 99.4%
FOR: 53,832,714AGAINST: 301,247

Prior year: 98.6% for (June 13, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: James J. Marino

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: James J. Marino”): 53,832,714 for, 301,247 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.4% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,431,614 for, 1,167 against, 9,367 abstained.

FOR
FOR: 27,431,614AGAINST: 1,167ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: James J. Marino” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Keith L. Brownlie

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 2 wordings of this item as funds reported it.

99.5% Majority: yes · of votes cast

FOR 99.5%
FOR: 53,883,737AGAINST: 250,401

Prior year: 98.8% for (June 13, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Keith L. Brownlie

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Keith L. Brownlie”): 53,883,737 for, 250,401 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,432,781 for, 9,367 abstained.

FOR
FOR: 27,432,781ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Keith L. Brownlie” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Elect Director: Rita I. Jain, M.D.

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.6% Majority: yes · of votes cast

FOR 99.6%
FOR: 53,914,572AGAINST: 207,007

Prior year: 98.9% for (June 13, 2024 meeting) ▲ 0.8 pts

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: Election of Directors: Rita I. Jain, M.D.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Rita I. Jain, M.D.”): 53,914,572 for, 207,007 against, per its Form 8-K filed June 6, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “The stockholders elected the following individuals to serve on the Company's board of directors until the annual meeting of stockholders to be held in 2026.”
Support: 99.6% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,432,781 for, 9,367 abstained.

FOR
FOR: 27,432,781ABSTAIN: 9,367
Largest asset managers voting on “Election of Directors: Rita I. Jain, M.D.” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,8100 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

An amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

98% Approved · of votes cast

FOR 98%
FOR: 53,158,156AGAINST: 963,067

Prior year: 97.2% for (June 13, 2024 meeting) ▲ 1.0 pts

Details: description as filed, official tally, votes by 57 asset managers

Description as filed by funds: To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“3. An amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares”): 53,158,156 for, 963,067 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 2,000,000 shares to 9,500,000 shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shar” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,77040 00For
Charles Schwab537,8230 00For
American Century0496,205 00Against
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust15,62419,391 00Mixed
ProShares32,9800 00For
Transamerica32,6680 00For

Fund voting reports, all 53 managers: 26,901,690 for, 531,091 against, 9,367 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 3 asset managers voting on “To approve an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of shar” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Kynam Capital Management, LP00 04,605,007Withhold
Eversept Partners, LP696,4990 00For
ALGERT GLOBAL LLC32,2000 00For

Institutional-manager reports, all 3 managers: 728,699 for, 4,605,007 withheld.

The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 53,482,418AGAINST: 626,666

Prior year: 98.3% for (June 13, 2024 meeting) ▲ 0.5 pts

Details: description as filed, official tally, votes by 191 asset managers

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in this Proxy Statement.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“Proposal 4: The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement.”): 53,482,418 for, 626,666 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company's named executive officers as disclosed in the Proxy Statement.”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 53 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,011,6641,146 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Fund voting reports, all 53 managers: 27,430,468 for, 2,313 against, 9,367 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 152 asset managers voting on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in t” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Wellington7,593,6550 00For
Fidelity5,276,3640 00For
Kynam Capital Management, LP00 04,605,007Withhold
Commodore Capital LP3,680,0000 00For
T. Rowe Price3,423,8000 00For
State Street2,294,6661,146 00For
BlackRock1,826,0840 00For
GEODE CAPITAL MANAGEMENT, LLC1,609,4880 00For
Novo Holdings A/S1,200,0000 00For
Woodline Partners LP1,188,4290 00For
PICTET ASSET MANAGEMENT SA1,028,9470 00For
Rock Springs Capital Management LP812,6530 00For
Deep Track Capital, LP767,3890 00For
Eversept Partners, LP696,4990 00For
Fisher Asset Management, LLC651,0610 00For
Redmile Group, LLC550,9660 00For
Charles Schwab537,8440 00For
American Century523,5220 00For
5AM Venture Management, LLC497,2700 00For
Nuveen429,1260 00For
Northern Trust425,9520 00For
Point72372,0700 00For
TFG Asset Management GP Ltd0288,650 00Against
JPMorgan185,2630 00For
AXA INVESTMENT MANAGERS UK Ltd0184,803 00Against

Institutional-manager reports, all 152 managers: 37,255,297 for, 704,387 against, 4,605,007 withheld, 125,332 abstained, 361 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.8% Approved · of votes cast

FOR 99.8%
FOR: 58,043,825AGAINST: 119,347

Prior year: 99.8% for (June 13, 2024 meeting) unchanged

Details: description as filed, official tally, votes by 53 asset managers

Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025.

CELLDEX THERAPEUTICS INC.’s own tally for this item (“2. The ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 58,043,825 for, 119,347 against — passed, per its Form 8-K filed June 6, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025.”
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 53 asset managers below reported 27,431,574 for, 1,207 against, 9,367 abstained.

FOR
FOR: 27,431,574AGAINST: 1,207ABSTAIN: 9,367
Largest asset managers voting on “To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm f” at CELLDEX THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard9,127,2820 00For
Fidelity5,686,4740 00For
MUTUAL FUND SERIES TRUST3,736,7840 00For
T. Rowe Price2,525,7420 00For
BlackRock1,930,8770 00For
State Street1,012,77040 00For
Charles Schwab537,8230 00For
American Century496,2050 00For
Hartford460,9830 00For
TIAA426,7100 00For
Equitable179,0480 00For
Northwestern Mutual115,6970 00For
AIG/SunAmerica112,7020 00For
QUANTITATIVE MASTER SERIES LLC108,9150 00For
JPMorgan102,4770 00For
John Hancock96,1100 00For
DWS95,7800 00For
Brighthouse94,7210 00For
Lincoln Financial52,7680 00For
MassMutual40,5040 00For
New York Life38,3430 00For
Global X37,9660 00For
Bridge Builder Trust35,0150 00For
ProShares32,9800 00For
Transamerica32,6680 00For

Showing the 25 largest of 53 asset managers. All 53 are in the interactive database (link above).

Largest CELLDEX THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 66,384,191 shares outstanding at the time of that meeting.

Fund voting reports: top CELLDEX THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 13.75%
2Fidelity 8.57%
3MUTUAL FUND SERIES TRUST 5.63%
4T. Rowe Price 3.80%
5BlackRock 2.91%
6State Street 1.53%
7Charles Schwab 0.81%
8American Century 0.75%
9Hartford 0.69%
10TIAA 0.64%
Institutional-manager reports: top CELLDEX THERAPEUTICS INC. shareholders by shares voted on “To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as…”, 2024-2025
#Asset manager % of shares outstanding
1Wellington 11.44%
2Fidelity 7.95%
3Kynam Capital Management, LP 6.94%
4Commodore Capital LP 5.54%
5T. Rowe Price 5.16%
6State Street 3.46%
7BlackRock 2.75%
8GEODE CAPITAL MANAGEMENT, LLC 2.42%
9Novo Holdings A/S 1.81%
10Woodline Partners LP 1.79%

Reported CELLDEX THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

CELLDEX THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Wellington Management8,354,151 12.58%Form 13F, quarter ended March 31, 2025
BlackRock5,524,132 8.32%Form 13F, quarter ended March 31, 2025
FMR (Fidelity)5,380,091 8.10%Form 13F, quarter ended March 31, 2025
FMR LLC4,857,668 7.32%Proxy statement (DEF 14A), proxy filed April 21, 2025
Vanguard Group3,898,435 5.87%Form 13F, quarter ended March 31, 2025
T. Rowe Price3,410,499 5.14%Form 13F, quarter ended March 31, 2025
COMMODORE CAPITAL LP3,350,000 5.05%Proxy statement (DEF 14A), proxy filed April 21, 2025
State Street2,806,359 4.23%Form 13F, quarter ended March 31, 2025
Point722,621,175 3.95%Form 13F, quarter ended March 31, 2025
Geode Capital1,589,806 2.39%Form 13F, quarter ended March 31, 2025

Percentages above are of 66,384,191 shares outstanding, as reported by CELLDEX THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At CELLDEX THERAPEUTICS INC.'s shareholder meeting held June 5, 2025, in the 2024-2025 proxy season, 191 asset managers reported votes on at least one of its 12 ballot items in their SEC Form N-PX filings, covering 2,712 separate fund positions. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — CELLDEX THERAPEUTICS INC.'s filing reports the proposal as approved, with 99% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: CELLDEX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 6, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from CELLDEX THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

CELLDEX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “CELLDEX THERAPEUTICS (CLDX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/celldex-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.